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Abstract
Background: Female sterilization by tubal ligation is a safe, extremely effective, and permanent way to limit
childbearing. It is the most popular modern contraceptive method worldwide. The simplest way to provide tubal
ligation is by a procedure called minilaparotomy, generally performed with the client under local anesthesia with
systemic sedation and analgesia. In Tanzania, unmet need for family planning is high and has declined little in the
past decade. Access to tubal ligation is limited throughout the country, in large part because of a lack of trained
providers. Clinical officers (COs) are midlevel health workers who provide diagnosis, treatment, and minor surgeries.
They are more prevalent than physicians in poorer and rural communities. Task shifting—the delegation of some
tasks to less-specialized health workers, including task shifting of surgical procedures to midlevel cadres—has
improved access to lifesaving interventions in resource-limited settings. It is a cost-effective way to address
shortages of physicians, increasing access to services. The primary objective of this trial is to establish whether
the safety of tubal ligation by minilaparotomy provided by COs is noninferior to the safety of tubal ligation by
minilaparotomy provided by physicians (assistant medical officers [AMOs]), as measured by rates of major adverse
events (AEs) during the procedure and through 42 days of follow-up.
Methods/design: In this facility-based, multicenter, noninferiority randomized controlled trial, we are comparing
the safety of tubal ligation by minilaparotomy performed by trained COs versus by trained AMOs. The primary
outcome is safety, defined by the overall rate of major AEs occurring during the minilaparotomy procedure and
through 42 days of follow-up. The trial will be conducted among 1970 women 18 years of age or older presenting
for tubal ligation at 7 study sites in northern Tanzania.
Discussion: If no major safety issues are identified, the data from this trial may facilitate changes in the Tanzanian
government’s regulations, allowing appropriately trained COs to provide tubal ligation by minilaparotomy. Positive
findings may have broader implications. Task shifting to provide long-acting contraceptives, if proven safe, may be
an effective approach to increasing contraceptive access in low- and middle-income countries.
Trial registration: ClinicalTrials.gov, NCT02944149. Registered on 14 October 2016.
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Background
Female sterilization by tubal ligation is a safe, extremely
effective, and permanent way to limit childbearing, and it is
the single most popular modern contraceptive method
worldwide [1]. The simplest way to provide tubal ligation is
through a procedure called minilaparotomy, which is gen-
erally performed with the client under local anesthesia with
systemic sedation and analgesia. According to the World
Health Organization (WHO), tubal ligation by minilaparot-
omy is a minor surgery that can be performed in resource-
limited settings on an outpatient basis with low risk of
complications [2, 3]. Although data are limited and pub-
lished reports are for the most part several decades old,
complication rates of 0.7–3.4% following tubal ligation by
minilaparotomy performed by physicians have been
reported in several countries in Africa [4–9].
Among currently married Tanzanian women 15–49
years old, 25.7% do not want to have any more children,
whereas 3.4% have had a tubal ligation [10]. Although
modern contraceptive use has steadily increased over
the last decade, from 20% in 2004–2005 to 27% in 2010
and 32% in 2015–2016, unmet need for family planning
has remained steady at 22–24% since 1999 [10]. Use of
tubal ligation among currently married women has more
than doubled, from 1.6% in the early 1990s to 3.4%
today; however, it represents only about 11% of all
contraceptive use, despite the large numbers of women
who desire no more children [10].
Despite a high demand for modern contraceptives,
access to tubal ligation in Tanzania is limited, with 58%
of hospitals and 38% of health centers offering tubal
ligation services. (In some cases, only counseling is pro-
vided.) Availability is roughly evenly divided between
government, private for-profit, and faith-based facilities
[11]. The government of Tanzania (GOT) recognizes
that most health facilities in the country are under-
staffed, with the greatest need in rural areas, and that a
lack of trained providers significantly limits the availabil-
ity of services, including tubal ligation [12]. Clinical offi-
cers (COs) are midlevel providers who diagnose and
treat illnesses and perform minor surgeries. They out-
number physicians, both medical officers (MOs) and
assistant medical officers (AMOs), by a 2:1 ratio, and
they are more prevalent in rural communities [11].
Task shifting, described as delegation or shifting of
some tasks to less-specialized health workers, is one
method used to expand the health workforce [13, 14].
Task shifting of surgical procedures to midlevel cadres,
including COs, has improved access to lifesaving inter-
ventions in resource-limited settings and is considered a
safe and cost-effective way to address physician short-
ages [15]. Two recent systematic reviews of older stud-
ies, as well as two recent small-scale studies in Uganda
and Malawi, suggest that task-shifting tubal ligation via
minilaparotomy to nonphysician clinicians is safe,
although available evidence is limited and well-designed
clinical trials are needed to definitively demonstrate
safety, efficacy, and acceptability of task-shifting the pro-
cedure to midlevel providers [16–19]. WHO guidelines
on optimizing health workers’ roles for maternal and
newborn health include COs among those considered
competent to provide tubal ligation; however, the recom-
mendation was not based on a review of evidence [20].
Task shifting of tubal ligation by minilaparotomy to
COs would increase access to tubal ligation for many
Tanzanian women who are most in need and is of inter-
est to the GOT as a way to assist in meeting the needs
of the growing numbers of women seeking permanent
contraception. With this in mind, the primary objective
of the present study is to establish whether the safety of
tubal ligation by minilaparotomy, as measured by rates
of major adverse events (AEs) during study participation,
when provided by trained COs is noninferior to the
safety of the procedure when provided by trained
AMOs.
Methods/design
This study is a noninferiority randomized controlled trial
(RCT) comparing the safety of tubal ligation by minila-
parotomy conducted by trained COs and by trained
AMOs in Tanzania. We will randomize a total of 1970
women 18 years of age and older presenting at 7 sites
for tubal ligation in a 1:1 ratio to have the procedure
done by a CO or an AMO. In addition to the screening
and enrollment/tubal ligation visit, there will be three
scheduled follow-up visits at 3, 7, and 42 days postsur-
gery. Figure 1 depicts the flow of study participants. We
have included a Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) checklist in
Additional file 1.
Intervention
The study intervention is tubal ligation via minilaparot-
omy conducted by a CO in the intervention arm and by
an AMO is the control arm. To ensure adequate skills
to perform minilaparotomy, COs and AMOs (none of
whom had prior experience performing tubal ligation by
minilaparotomy) participated in competency-based
training according to GOT guidelines and standards
prior to the start of the study [21].
Outcome measures
The primary objective is to establish whether the safety
of tubal ligation by minilaparotomy as provided by COs
is noninferior to the safety of tubal ligation by minilapar-
otomy as provided by AMOs. The primary study out-
come is safety, defined by the overall rate of major AEs
observed during the procedure and through 42 days of
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follow-up. We will compare the rate of major AEs ob-
served following procedures conducted by COs with that
of procedures performed by AMOs. Major AEs include
the following:
1. Injuries to abdominal viscera, pelvic abscess, or
severe peritonitis leading to unintended major
surgery
2. Severe intra- or immediate postoperative
hemorrhage requiring blood transfusion
3. Febrile morbidity (oral temperature > 38 °C on at
least 2 postoperative days, excluding the first 24 h
after surgery)
4. Life-threatening event (including cardiopulmonary
crisis or anaphylaxis)
5. Readmission to the hospital any time after discharge
after the procedure through the end of follow-up,
owing to a complication related to the minilaparot-
omy procedure
6. Death or complication resulting in death occurring
within 42 days of the surgery related to the
minilaparotomy procedure
Secondary objectives and their outcomes include com-
parison of the following:
1. The safety of tubal ligation by minilaparotomy
provided by COs versus AMOs as measured by AE
rates (major and minor) at different points in time
(intraoperatively, immediately postoperatively, and at
each follow-up visit)
2. The performance (e.g., procedure times, difficulties
performing the procedure, inability to complete the
procedure, need for assistance to complete the
procedure, and maximum reported pain experienced
by the participant during the procedure) of COs
versus AMOs for conducting tubal ligation by
minilaparotomy
3. Participant satisfaction with the tubal ligation
conducted by COs versus AMOs
4. The self-efficacy of COs versus AMOs in performing
tubal ligation by minilaparotomy, defined by pro-
vider confidence, comfort, and perception of their
ability to perform the procedure
Detailed definitions of the primary and secondary out-
comes, including the domain (name of the outcome),
specific measurement, metric, method of aggregation,
and time point for measurement can be found in
Table 1.
Study sites
We will conduct the study at seven sites based at health
care facilities in northern Tanzania (Table 2). In addition
to provision of tubal ligation services at these seven
static sites, we will use outreach approaches that are cur-
rently part of the GOT’s approach to increasing access
to family planning. During outreach events, the trained
COs and AMOs from the seven static study sites will
travel to and perform procedures at other facilities
where tubal ligation is not routinely available. All seven
of the static study sites, as well as the outreach sites, are
currently part of the GOT family planning program, with
tubal ligation by minilaparotomy normally provided by
physicians who are not among the providers included in
the study.
Fig. 1 Trial profile
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Study population and eligibility criteria
We will recruit a total of 1970 participants from among
women presenting at static or outreach study sites for
tubal ligation. Study staff will ask women if they are
potentially interested in participating in the study after
they have undergone the standard GOT family planning
counseling, chosen tubal ligation as the contraceptive
option of their choice, and signed the GOT informed
consent documents for the tubal ligation procedure.
We will randomize women if they meet any of the fol-
lowing criteria:
1. Are aged 18 years or older
2. Requested and consented (in accordance with GOT
procedures) to tubal ligation and additionally freely
consented to participate in the study and signed a
study informed consent form
3. Are of sound mind, are in good general health, and
are deemed suitable to undergo tubal ligation by
minilaparotomy in accordance with the GOT
guidelines [21]
4. Are able to understand study procedures and the
requirements of study participation
5. Agree to return to the study site for the full
schedule of follow-up visits
6. Agree to provide the study staff with an address,
phone number, name of a close relative, and/or
other locator information while participating in the
research study
We will exclude women if they meet any of the follow-
ing criteria:
1. Are pregnant
2. Are between 8 and 42 days postpartum or
postabortion
3. Have a known allergy or sensitivity to lidocaine or
other local anesthesia
4. Take a medication that would be a contraindication
for elective surgery, such as an anticoagulant or
steroid
5. Have had previous abdominal or pelvic surgery
6. Have a local skin infection near the area where the
incision will be made
7. Have severe anemia (regardless of type or etiology),
a coagulation disorder, hypertension (properly taken
measurements: systolic pressure ≥ 160 mmHg or
diastolic pressure ≥ 100 mmHg), acute deep venous
thrombosis/pulmonary embolism, or current
ischemic heart disease
8. Have unexplained vaginal bleeding; malignant
gestational trophoblastic disease; cervical,
endometrial, and/or ovarian cancer; pelvic
inflammatory disease (current or within the last
3 months); or current purulent cervicitis, chlamydial
infection, and/or gonorrhea
9. Have current symptomatic gallbladder disease, active
viral hepatitis, tuberculosis of pelvic organs, acute
bronchitis or pneumonia, or systematic infection or
gastroenteritis
10.Are currently participating in another biomedical
research study
Generation of allocation sequence and random allocation
We used permuted blocks within the site for the
randomization to ensure similarity of groups with regard
to potential confounding factors. A researcher unaffili-
ated with the study generated by computer the random
allocation sequence centrally at EngenderHealth head-
quarters in New York City. Randomization is in a 1:1
ratio (minilaparotomy conducted by a CO or minilapar-
otomy conducted by an AMO), stratified by study site,
and restricted with randomly varying block sizes of four
to eight within the strata. We will recruit participants at
all study sites until the total sample size has been
reached. A research assistant at each site will randomize
participants after screening has been conducted, a
woman’s eligibility for study participation has been con-
firmed, and just prior to start of the minilaparotomy
procedure. We will achieve random allocation conceal-
ment by using a text message service (Sealed Envelope
Ltd. [www.sealedenvelope.com], London, UK). Because
of the nature of the services and low availability of clin-
ical staff at study sites, it is not possible to mask partici-
pants, coinvestigators, those assessing outcomes, or
other study staff to treatment allocation.
Rationale for the noninferiority hypothesis and sample
size calculation
The primary objective of this study is to determine
whether the rate of major AEs following tubal ligation
by minilaparotomy conducted by trained COs is not
worse by more than a minimal relevant difference than
the AE rate following tubal ligation by minilaparotomy
conducted by trained AMOs. This question lends itself
to a noninferiority design. The choice of the
Table 2 Study sites
District Static study site
Arusha City Daraja 2 Health Centre
Kaloleni Health Centre
Levolosi Urban Health Centre
Karatu District Karatu Designated District Hospital
Longido District Longido Health Centre
Monduli District Monduli District Hospital
Mto wa Mbu Health Centre
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noninferiority margin (i.e., the smallest clinical difference
that is acceptable between the two treatments) is based
on a combination of clinical judgment and statistical rea-
soning. In the case of major AEs following tubal ligation
by minilaparotomy, data from prior trials (n = 12) sug-
gest an average AE rate of 3.85% (95% CI 3.15–4.54%).
After removing the one trial that is an outlier, in terms
of both sample size and AE rate, we calculated the aver-
age as 1.59% (95% CI 0.90–2.28%) (Table 3).
These data suggest that an absolute rate of approxi-
mately 3% would be expected and that we would expect
no greater than 5%, based on the upper limit of the 95%
CI. In addition, in the clinical judgment of Engender-
Health staff and outside experts, we have determined
that a noninferiority margin of 2% is appropriate because
it implies that up to a 5% AE rate would be clinically
acceptable. In other words, if the upper limit of the two-
sided 95% CI for the difference in AE rates (CO minus
AMO) lies fully to the left of the 2% noninferiority mar-
gin, we will have proved noninferiority of tubal ligation
by minilaparotomy conducted by COs at a level of sig-
nificance of α = 0.05.
Assuming a 3% major AE rate in the control group
(AMOs), we will demonstrate noninferiority within the
margin of 2% at a one-sided significance level of α = 0.05
and a power of 80% (calculated when AE rates in both
arms are the same) with a sample size of 895 per arm
(1790 women in total). Adjusting by 10% for loss to
follow-up, protocol violations, and withdrawals, this
would result in a total sample size of 1969 women,
rounded to 1970.
Data collection procedures and participant pathway
Data will be collected for all women who consent to
participate using electronic case report forms (eCRFs)
we developed for the study and programmed with Open
Data Kit Collect (University of Washington, Department
of Computer Science and Engineering, Seattle, WA,
USA; https://opendatakit.org/) on Tecno PhonePad 7II
tablets (TECNO Mobile, Hong Kong, China; www.tecno-
mobile.com). A summary of the schedule of enrollment,
interventions, and assessments is shown in Table 4. We
trained study staff on data collection using the eCRFs
prior to the start of recruitment. We will routinely assess
the data throughout the study for inconsistencies and
common errors as well as to identify missing values or
missing records. We will resolve missing data to the great-
est extent possible.
After informed consent has been obtained by a
research assistant, a study provider will evaluate each
Table 3 Reported adverse event rates following tubal ligation
by minilaparotomy
Reference AEs (n) Sample (n) AE rate
Chowdhury and
Chowdhury,
1975 [31]
7 600 1.2%
Fongsri and
McDaniel,
1979 [32]
4 900 0.4%
Dusitsin et al.,
1980 [33]
5 292 1.7%
Koetsawang et al.,
1981 [34]
37 1376 2.7%
Satyapan et al.,
1983 [35]
82 3549 2.3%
Kanchanasinith et al.,
1990 [36]
8 820 1.0%
Jack and Chao,
1992 [8]
482 5182 9.3%
Ruminjo and Ngugi,
1992 [6]
8 1521 0.5%
Ruminjo and Ngugi,
1993 [5]
30 1999 1.5%
Cisse et al., 1997 [4] 7 800 0.9%
Kidan et al., 2001 [9] 0 148 0.0%
Gordon-Maclean et al.,
2014 [18]
11 518 2.1%
AE rate
(weighted
average)
Lower
limit
Upper
limit
Total 681 17,705 3.85% 3.15% 4.54%
Total excluding Jack
and Chao, 1992 [8]
199 12,523 1.59% 0.90% 2.28%
AE Adverse event
Table 4 Schedule of enrollment, interventions, and assessments
Study period
Enrollment Allocation Postallocation
Time pointa Day 0 Day 0 Day
0
Day
3
Day
7
Day
42
Enrollment
Eligibility screen X
Informed consent X
Allocation X
Interventions
Procedure by CO X
Procedure by AMO X
Assessments
Pregnancy test X
Directed physical
examination
X X X X
Adverse events X X X X
Interview X X
AMO Assistant medical officer, CO Clinical officer
aIn most cases, screening, enrollment, allocation, and the tubal ligation by
minilaparotomy procedure will all be done on the same day (designated as
day 0)
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potential participant for clinical eligibility according to the
study inclusion and exclusion criteria noted above. If eli-
gible, a research assistant will randomize participants, and
the minilaparotomy procedure will be done on the same
visit in most cases (or, if not, within 7 days of screening).
Providers will conduct tubal ligation procedures according
to the GOT guidelines [21]. We have not placed any re-
strictions on clinical care that a provider deems necessary
for the health and well-being of study participants, al-
though we will collect data on all relevant concomitant
care and interventions provided before or during the pro-
cedure, as well as during the follow-up period.
We will ask participants to return for three scheduled
follow-up visits at 3, 7, and 42 days postsurgery. A
research assistant will call or text participants the day
before each scheduled visit to remind them to come for
follow-up. If a participant misses a visit, a research
assistant will attempt to contact the participant three
times to encourage him/her to come for the visit. We
will give participants 5000 Tanzanian shillings (approxi-
mately $2.25) to cover time and transport cost to/from
the study site for each of the three scheduled follow-up
visits. A provider may schedule additional visits if clinic-
ally necessary, and we will inform participants that they
should return to the site at any time if they have prob-
lems or concerns related to the procedure.
We will collect data at three time points:
1. Prior to the minilaparotomy procedure, we will
record detailed information on sociodemographic
characteristics, obstetric and family planning
use history, and physical examination findings.
2. At the time of surgery, we will gather details of the
anesthesia and procedure, including problems
encountered, assistance needed, and occurrence of AEs.
3. We will record information on physical examination
findings, AEs, and participants’ experience and
satisfaction postsurgery; during recovery; and at 3, 7,
and 42 days after surgery, as well as during any
unscheduled follow-up visits.
4. At the end of the study, we will collect information
from the COs and AMOs on self-efficacy, including
measures of general self-efficacy, and confidence and
comfort conduting minilaparotomy.
Once an individual eCRF is completed, a research
assistant will encrypt the data on the tablets and upload
it through a secure connection to the database located
on a server in EngenderHealth’s office in Dar es Salaam,
Tanzania. Detailed procedures for the collection, man-
agement, and use of the data are outlined in a study data
management plan.
Providers will assess participants for the presence of AEs
during the minilaparotomy procedure and postoperative
period, as well as at all scheduled and unscheduled follow-
up visits, and provide treatment/referral and follow-up as
clinically indicated. We will collect detailed data on AEs
in the eCRFs, including type, severity, relatedness to the
minilaparotomy procedure, treatment, and outcome. We
will report serious AEs resulting in death to the institu-
tional review boards (IRBs) within 24 h of when the prin-
cipal investigator (PI) is notified and those resulting in
hospitalization within 10 days of notification of the PI.
We will also monitor for social harm events (SHEs) such
as loss of privacy, stigmatization, relationship difficulties,
physical or verbal abuse, and interference with gainful em-
ployment. We will help participants address any reported
SHEs or refer them to available support services appropri-
ate for the SHE. We will report SHEs potentially related
to study participation to the IRBs within 10 days of when
the PI is notified. During the study, an independent clin-
ical trial monitor will conduct periodic on-site monitoring
visits as needed to ensure that the study is being con-
ducted and informed consent is being obtained according
to the approved protocol, good clinical practice standards,
and applicable regulatory guidelines, as well as to monitor
recruitment and data quality.
Statistical methods
We will develop a detailed analysis plan that covers both
the final analysis and the planned interim analysis prior to
initiation of the analysis. The primary outcome of the trial
is major AEs within 42 days of the tubal ligation by mini-
laparotomy (i.e., the proportion of participants experien-
cing a major AE by day 42 postsurgery) in an intention-
to-treat (ITT) analysis. We will conduct the primary ana-
lysis for the ITT population. The ITT population would
include participants for whom the protocol is violated (i.e.,
participants who are randomized to have their procedure
done by a CO but in fact have the procedure done by an
AMO, or participants who are randomized to have their
procedure done by an AMO but in fact have the proced-
ure done by a CO) and withdrawals/discontinuations. We
will also conduct a per-protocol analysis for the primary
outcome if we have participants who do not receive the
treatment to which they were randomly allocated.
Unlike a superiority trial, where the treatment effect is
the primary parameter of interest, the interpretation of a
noninferiority trial’s results depends on the location of
the CI for the effect of the experimental treatment rela-
tive to the margin of noninferiority and a null effect
[22]. The primary analysis will be interpreted as follows.
If the whole 95% CI lies above the noninferiority margin
of 2%, the experimental intervention will be declared
“inferior.” If the whole 95% CI lies below the noninferi-
ority margin, the intervention will be considered to be
“noninferior” to the standard treatment. If the 95% CI
includes the noninferiority margin, study results will be
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deemed inconclusive. Finally, if the entire 95% CI lies
completely below zero, the new treatment may be con-
sidered superior to the standard treatment.
We will conduct other analyses on primary and sec-
ondary outcomes related to tubal ligation by minilapar-
otomy, including AE rates (overall and per time point),
measures of performance (e.g., procedure times, difficul-
ties performing the procedure, inability to complete the
procedure), and participant satisfaction. We will analyze
data on key demographic and reproductive variables
(e.g., age, education level, marital status, occupation, eth-
nicity, parity) to generate a profile of study participants
undergoing tubal ligation by minilaparotomy at study
sites. We will analyze data on key provider-level vari-
ables to generate a profile of providers, disaggregated by
provider type (CO and AMO). Methods of analysis for
each secondary outcome are shown in Table 1 above.
We will include data in the analyses for all outcomes
for participants who withdraw or are discontinued in the
study through the time their study participation ends.
We will not consider observations with missing data in
the analyses and will not impute any missing data.
We have recruited a three-member data and safety
monitoring board (DSMB) with no direct involvement in
the study, including a surgeon experienced with tubal
ligation by minilaparotomy, an epidemiologist, and a stat-
istician. The role of the DSMB will be to deal with any
ethical and safety issues that may arise during the trial and
to review an interim analysis. We will conduct the interim
analysis after approximately one-third of the sample has
had the minilaparotomy procedure and completed the 7-
day follow-up visit. At the time of the interim analyses, we
will provide the DSMB with safety and study quality data
(e.g., recruitment and follow-up rates, protocol violations),
unmasked by treatment group.
We will ask the DSMB to give advice regarding stop-
ping the trial if they have proof beyond doubt of an
important advantage or disadvantage for one of the
treatment groups and if they consider that the results
are likely to affect clinical practice. For the primary out-
come (i.e., major AEs), the following stopping guidelines
have been proposed for the DSMB:
1. At the time of the interim analysis, the DSMB may
recommend stopping the study or temporarily halting
recruitment if there are significantly more major AEs
in one randomization group than in the other; a
difference between the two treatment arms will be
considered significant if the p value is < 0.001 [23].
2. In the event that the interim analysis shows notably
higher rates of major AEs in the study participants
overall (i.e., both study arms) relative to the
generally accepted AE rates following tubal ligation
by minilaparotomy (e.g., a > 5% rate, which is the
upper limit of the 95% CI in previously published
studies), the DSMB may recommend stopping the
study or temporarily halting recruitment.
3. The DSMB may also recommend stopping the study,
temporarily halting recruitment, or adjusting study
sites if it seems that recruitment is not proceeding at
rates that will allow the study to reach its target
sample size within a reasonable time frame.
If the study is stopped temporarily or permanently for
any reason, we will continue to follow participants
already enrolled for the planned follow-up period (and
longer, if necessary, based on clinical indications). We
will continue to provide enrolled participants with clin-
ical care as necessary. According to the charter agreed
to by the DSMB members before the start of the trial,
their role will be as advisors to the investigators; the lat-
ter will be responsible for making decisions regarding
temporarily or permanently stopping recruitment.
The PI will have responsibility for informing relevant
parties (e.g., other investigators, study site personnel,
IRBs, trial participants, trial registries), or ensuring they
are informed, of any important protocol modifications
or other information pertinent to conduct of the trial via
email or phone or in person in a timely fashion, depend-
ing on the nature and urgency of the information.
Discussion
If no major safety or other issues are identified, the data
from this trial may facilitate changes in the GOT regula-
tions, allowing appropriately trained COs to provide
tubal ligation by minilaparotomy. We have reason to be
optimistic that COs will be able to safely perform tubal
ligations by minilaparotomy. As mentioned previously,
two recent systematic reviews and results of two recent
small-scale studies provide data supporting the safety of
task-shifting tubal ligation by minilaparotomy to non-
physician clinicians [16–19]. Moreover, surgical task-
shifting initiatives have been reported to be successful in
various African countries, including Malawi [24],
Mozambique [25–27], and Tanzania [28], with COs and
nurses demonstrating success similar to that of their
higher-level counterparts in performing cesarean deliver-
ies and other major surgical procedures more complex
than tubal ligation by minilaparotomy.
If our results demonstrate that tubal ligation by mini-
laparotomy provided by COs is noninferior to provision
by AMOs, leading to revised guidelines by the GOT and
training of COs to provide tubal ligation by minilaparot-
omy in Tanzania, access to a very effective permanent
method of contraception would increase dramatically for
thousands of women, given the more widespread avail-
ability of COs at health facilities around the country
relative to physicians. Three-fourths of the population of
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Tanzania lives in rural areas; yet, only 31% of physicians
are stationed in rural areas, in contrast to 72% of COs
[29]. The need for female surgical contraceptive services
in Tanzania is critically urgent. If current trends con-
tinue, the number of women of reproductive age (15–49
years old) choosing female sterilization by 2020 will be
more than 65,000 annually, almost a doubling of
demand since 2011 [30].
Positive findings may have broader implications; task
shifting to provide long-term contraceptives, if proven
safe, may be an effective approach to increasing contra-
ceptive access in many low- and middle-income coun-
tries. The results of our large-scale RCT will provide
definitive data to support or refute provision of tubal
ligation by minilaparotomy conducted by nonphysician
clinicians and may lead to changes in government regu-
lations in a variety of countries.
Following completion of the study, we will submit a report
to United States Agency for International Development/
Tanzania and to the GOT. Additionally, we will prepare
policy and technical briefs for dissemination to a wide
audience, dependent on the outcome of the study. Regard-
less of study outcomes, the research team will hold dissem-
ination meetings with key district, regional, and national
stakeholders in Tanzania. Given the likely wide potential
interest and importance of the results in the international
family planning community, we will also disseminate the
results in at least one publication in a peer-reviewed journal
and at one or more international scientific conferences. We
will follow the authorship guidelines of the International
Committee of Medical Journal Editors, whereby each author
is required to (1) have made substantial contributions to the
conception or design of the work or to the acquisition,
analysis, or interpretation of data for the work; (2) have
made substantial contributions to drafting the work or revis-
ing it critically for important intellectual content; (3) approve
the final version to be published; and (4) agree to be
accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part of
the work are appropriately investigated and resolved. We do
not intend to use professional writers.
We do not plan to disseminate the results among
research participants, because the vast majority will not be
returning to the facility after their final follow-up visit is
complete. Moreover, the intervention being tested is a ser-
vice delivery approach and is not related to participant be-
haviors; thus, the communities of interest for dissemination
of results are government officials, policymakers, and family
planning program managers and providers.
Trial status
Enrollment began on 6 December 2016 and was com-
pleted on 16 June 2017. Follow-up was completed on 28
July 2017.
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Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) checklist. (DOC 124 kb)
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